An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome



Status:Active, not recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:1 - 18
Updated:3/21/2019
Start Date:March 16, 2015
End Date:December 31, 2019

Use our guide to learn which trials are right for you!

A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome
who have completed participation in a core LUM001 treatment protocol. The primary objective
is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by
evaluating the effect of LUM001 on the biochemical markers and pruritus associated with
Alagille Syndrome.


Inclusion Criteria:

1. Male or female, 12 months to 18 years of age.

2. Competent to provide informed consent and assent (per institutional review
board/Ethics Committee [IRB/EC]), as appropriate.

3. Completed participation in the LUM001-301 protocol.

4. Females of childbearing potential must have a negative urine pregnancy test [beta
human chorionic gonadotropin (beta-hCG)] at the Baseline Visit.

5. Sexually active females must be prepared to use an effective method of contraception
during the trial.

Effective methods of contraception are considered to be:

1. Hormonal (for example, contraceptive pill, patch, intramuscular implant or
injection); or

2. Barrier method, for exampe, (a) condom with spermicide, or (b) diaphragm, with
spermicide; or

3. Intrauterine device (IUD).

6. Participants above the age of assent and caregivers and children must be able to read
and understand English or Spanish.

7. Caregivers (and age appropriate participants) must have access to phone for scheduled
calls from study site.

8. Caregivers (and age appropriate participants) must be willing and able to complete a
daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and
then for 4 consecutive weeks following the Week 24 and Week 44 visits.

9. Caregivers (and age appropriate participants) must digitally accept the licensing
agreement in the ItchRO electronic diary software at the outset of the study.

10. Eligible participants must be able to adhere to local Ethics Committee or
Institutional Review Board (IRB) blood volume limits for laboratory testing.

11. The participant has completed the protocol either through Week 144, or the End of
Trial visit, or has received permission from the sponsor and the Premier Medical
monitor to re-enter the study in the long-term, optional follow-up treatment period 2.

12. Females of child-bearing potential must have a negative urine or serum pregnancy test
(beta-HCG]) at the time of entry into the long-term optional follow-up treatment
period 2.

13. Male and female participants of child-bearing potential who are sexually active, or
are not currently sexually active, but become sexually active during the study or for
30 days following the last dose of study drug, must agree to use acceptable
contraception during the study.

14. Informed consent and assent (per IRB/EC) as appropriate.

15. Caregivers (and age appropriate participants) must have access to phone for scheduled
calls from study site.

16. Caregivers (and age appropriate participants) must be willing to follow the rules of
eDiary completion.

Exclusion Criteria:

1. Experienced an adverse event or serious adverse event (SAE) related to the study drug
during the LUM001-301 protocol that led to the discontinuation of the participant from
the core study.

2. Any conditions or abnormalities (including laboratory abnormalities) which in the
opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may
compromise the safety of the participant, or interfere with the participant
participating in or completing the study.

3. History or known presence of gallstones or kidney stones.

4. History of non-adherence during the participant's participation in the LUM001-301
protocol. Non-adherence is defined by dosing compliance (dosing compliance is
calculated by [the total number of doses that were actually taken by the participant]
divided by [the total number of doses that should have been taken by the participant]
multiplied by 100) of less than 80% in the LUM001-301 protocol.

5. Unlikely to comply with the study protocol, or unsuitable for any other reason, as
judged by the investigator.

6. All above exclusion criteria will apply upon re-entry into the long-term, optional
follow-up treatment period 2.
We found this trial at
13
sites
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Phone: 801-585-9495
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Phone: 513-803-0675
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Phone: 323-361-4566
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Phone: 267-426-0970
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Phone: 412-478-8294
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1405 Clifton Road NE
Atlanta, Georgia 30322
404-785-6000
Phone: 404-785-6027
Children's Healthcare of Atlanta Whether treating a toddler in an emergency or supporting a teen...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Phone: 720-777-4030
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Phone: 800-543-7362
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Houston, Texas
Phone: 832-824-3848
?
mi
from
Houston, TX
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Phone: 317-944-9605
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-476-7114
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Phone: 206-987-1037
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
Phone: 416-813-7654
?
mi
from
Toronto,
Click here to add this to my saved trials